Curium to buy Lantheus in all-cash deal worth up to $8bn
Curium, backed by CapVest Partners, agreed to buy Nasdaq-listed Lantheus in an all-cash deal worth up to about $8bn. Curium will pay $102.50 per share at closing plus non-transferable CVRs up to $12.00 per share, totaling $114.50. The offer includes premiums of 29% to 38% versus recent averages and needs regulatory and shareholder approvals, expected to close in H1 2027.
How this was made
The 30-second read
Why it matters
For LNTH, the key tradable input is the disclosed per-share cash consideration plus CVR upside, alongside the stated premiums and board approval. For CRYM, the key inputs are deal size, financing approach, and strategic fit, which will influence deal-risk perception and financing sensitivity.
Market read
This is a primary M&A disclosure with explicit consideration, premiums, board approval, and a stated closing window, which typically drives immediate deal-spread and valuation repricing.
What to watch
Financing mix (debt and equity) could affect CRYM’s cost of capital and deal economics; CVR mechanics depend on commercial milestones through 2030, which can be hard to underwrite.
Background
Curium, backed by CapVest Partners, has agreed to acquire Lantheus in an all-cash transaction that will take Lantheus private, with contingent value rights tied to product commercial milestones.
Ticker impact
Curium agreed to buy Lantheus for $102.50 per share in an all-cash deal, taking it private, with potential CVRs to $114.50.
Likely positive bias for LNTH while deal certainty rises; volatility tied to approval milestones and financing details.
The article discloses concrete per-share consideration, premium levels, board approval, and expected close timing, which typically drives immediate repricing toward offer value.
Market effects
Signals consolidation in radiopharmaceuticals and potential acceleration of theranostics scale and US diagnostic commercialization.
Strengthens US footprint for the combined entity, potentially reshaping competitive dynamics in US radiodiagnostics.
Combines global manufacturing and theranostics capabilities across more than 70 countries, potentially affecting international supply and partnerships.
Counterpoint
Offer value may not fully de-risk downside if regulatory review or shareholder votes introduce meaningful probability of delay or modification.
Key entities
- acquirerCurium
CapVest Partners-backed radiopharmaceutical company agreeing to buy Lantheus for up to nearly $8bn in an all-cash deal.
- targetLantheus
US-based radiopharmaceutical company to be taken private via an all-cash purchase at $102.50 per share plus CVRs up to $12.00.
- executiveMary Anne Heino
Lantheus executive chair and CEO who endorsed the transaction.
- executiveRenaud Dehareng
Curium CEO who described strategic rationale for the combination.
